The present invention relates to a protein called Tat related engineering (TAPE) method, the target protein and antibiotic resistance protein linked to Tat signal sequence and its expression in Escherichia coli, screening target protein has higher solubility and excellent thermal stability, especially the immunoglobulin variable domain from human reproduction cells (VH or VL), as well as people or transformation with solubility and excellent thermal stability screening by TAPE method, VH and VL domains of antibody and human or modified VH and VL domain antibody stent. Libraries of random CDR sequences included in an VH or domain antibody holder, as well as a process for their preparation, are also provided for screening in a TAPE or VL domain antibody holder. Haitong has a VH or VL domain antibody screened with the library for targeting protein binding capability, and a pharmaceutical composition comprising the domain antibody.
【技术实现步骤摘要】
超稳定免疫球蛋白可变结构域的筛选和改造方法及其应用本申请为2012年8月22日递交的申请号为201280076586.9并且专利技术名称为“超稳定免疫球蛋白可变结构域的筛选和改造方法及其应用”的专利技术专利申请的分案申请。
以下公开涉及被称作Tat相关蛋白质改造工程(TAPE)的方法,通过将靶蛋白和抗生素抗性蛋白融合到Tat信号序列并在大肠杆菌内表达它,筛选具有更高的溶解性和优异的热稳定性的靶蛋白,特别是源自人种系的免疫球蛋白可变结构域(VH或VL)。本专利技术还涉及由TAPE法筛选的、具有优异的溶解性和热稳定性的、人重链可变结构域抗体(下文称为“VH结构域抗体”)和轻链可变结构域抗体(下文称为“VL结构域抗体”)和人或改造的VH和VL结构域抗体支架。此外,以下公开内容涉及VH和VL结构域抗体和抗体支架的氨基酸序列,以及编码所述氨基酸序列的多核苷酸。在含有根据本专利技术筛选的人或改造的VH或VL支架的VH或VL结构域抗体具有相应的人或改造的VH或VL结构域抗体支架(不管CDR序列)的情况下,它仍保留溶解性和热稳定性。此外,以下公开内容涉及在由TAPE法筛选的人或改造的VH或VL结构域抗体支架中包括随机CDR序列的文库,以及其制备方法。此外,以下公开内容涉及使用所述文库筛选的、对靶蛋白质具有结合能力的VH或VL结构域抗体,所述结构域抗体的氨基酸序列,编码所述氨基酸序列的多核苷酸。专利技术背景片段化的小尺寸抗体因为它与全长单克隆抗体(mAb)的不同理化性质而是一种能够克服现有抗体疗法的局限性的有前途的抗体。存在单链抗体(scFv)、Fab(片段抗体结合)抗 ...
【技术保护点】
一种可溶性VH结构域抗体支架,具有下面的FR1至FR4的氨基酸序列:(1)FR1:X0VQLX1X2X3GX4X5X6X7X8PGX9SX10X11X12X13CX14X15X16GX17X18X19在FR1的氨基酸序列中,X0是E或Q,X1是V或L,X2是E,或Q,X3是S,或A,X4是G,或A,X5是G,M,N,V,或E,X6是L,V,或W,X7是V,K,A,或I,X8是Q,K,或H,X9是G,T,A,R,E,S,或T,X10是L,V,R,或M,X11是R,或K,X12是L,I,或V,X13是S,A,或T,X14是A,E,V,R,I,K,T,或S,X15是A,G,P,V,或T,X16是S,F,或Y,X17是F,Y,R,G,或L,X18是T,A,S,N,T,P,I,N,H,或A,X19是F,L,V,或C;(2)FR2:WX20RX21X22PGX23GX24X25X26X27X28在FR2的氨基酸序列中,X20是V,A,或L,X21是Q,N,R,I,K,Y,V,M,S,Q,W,F,L,V,或C,X22是A,G,K,S,V,M,或T,X23是K,Q,E,R,或T,X24是L,N,I,P ...
【技术特征摘要】
1.一种可溶性VH结构域抗体支架,具有下面的FR1至FR4的氨基酸序列:(1)FR1:X0VQLX1X2X3GX4X5X6X7X8PGX9SX10X11X12X13CX14X15X16GX17X18X19在FR1的氨基酸序列中,X0是E或Q,X1是V或L,X2是E,或Q,X3是S,或A,X4是G,或A,X5是G,M,N,V,或E,X6是L,V,或W,X7是V,K,A,或I,X8是Q,K,或H,X9是G,T,A,R,E,S,或T,X10是L,V,R,或M,X11是R,或K,X12是L,I,或V,X13是S,A,或T,X14是A,E,V,R,I,K,T,或S,X15是A,G,P,V,或T,X16是S,F,或Y,X17是F,Y,R,G,或L,X18是T,A,S,N,T,P,I,N,H,或A,X19是F,L,V,或C;(2)FR2:WX20RX21X22PGX23GX24X25X26X27X28在FR2的氨基酸序列中,X20是V,A,或L,X21是Q,N,R,I,K,Y,V,M,S,Q,W,F,L,V,或C,X22是A,G,K,S,V,M,或T,X23是K,Q,E,R,或T,X24是L,N,I,P,Y,T,V,W,A,R,M,或S,X25是V,或E,X26是W,I,V,P,F,H,M,Y,L,C,或R,X27是V,M,I,或L,X28是S,A,或G;(3)FR3:X29X30X31X32X33X34X35X36X37X38X39X40X41X42X43X44X45X46X47X48X49X50X51DX52X53X54YX55CX56X57在FR3的氨基酸序列中,X29是R,H,Q,或T,X30是F,V,L,或I,X31是T,S,或I,X32是I,L,V,M,或R,X33是S,T,或D,X34是R,A,V,N,或I,X35是D,N,或A,X36是N,T,D,I,R,K,Y,或E,X37是A,S,V,或T,X38是K,R,T,Q,V,E,M,N,或I,X39是N,R,T,K,S,D,或V,X40是T,M,S,V,I,Y,或A,X41是L,V,A,或M,X42是F,Y,N,D,H,或S,X43是L,或M,X44是Q,E,H,或N,X45是M,L,V,I,或W,X46是N,T,K,D,Y,I,或S,X47是S或N,X48是L或V,X49是R,K,或T,X50是D,A,S,P,T,V,I,或S,X51是E,A,D,或S,X52是T,N,或S,X53是S,A,或G,X54是V,I,L,或M,X55是Y或F,X56是A,G,V,或S,X57是R,S,K,T,L,N,或F;和(4)FR4:X58GX59GX60X61VTVSS在FR4的氨基酸序列中,X58是W,C,Y,G,S,或A,X59是Q,R,或L,X60是A,T,I,或V,X61是L,M,P,V,或T。2.根据权利要求1的VH结构域抗体支架,其中所述FR1至FR4具有下面的氨基酸序列:(1)FR1:X0VQLX1X2SGGX5X6X7X8PGX9SX10RX12SCX14X15SGX17X18X19在FR1的氨基酸序列中,X0是E或Q,X1是V或L,X2是E或Q,X5是G,N,V,或E,X6是L或V,X7是V或K,X8是Q,K或H,X9是G,T,A,R,E,或T,X10是L或V,X12是L或V,X14是A,E,V,I,K,或S,X15是A,G,或V,X17是F,Y,R,G,或L,X18是T,A,S,N,T,P,I,N,H,或A,和X19是F,L,V,或C;(2)FR2:WVRX21X22PGX23GX2...
【专利技术属性】
技术研发人员:李滢权,金圣根,朴荣燮,南效廷,金董植,朴在燦,尹桦,
申请(专利权)人:财团法人牧岩生命工学研究所,
类型:发明
国别省市:韩国,KR
还没有人留言评论。发表了对其他浏览者有用的留言会获得科技券。